Terms: = Lymphoma AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
27 results:
1. Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
Lu X; Emond B; Qureshi ZP; Wu LH; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Rogers KA
Curr Med Res Opin; 2023 Sep; 39(9):1227-1235. PubMed ID: 37530387
[TBL] [Abstract] [Full Text] [Related]
2. [Blaps rynchopetera affects proliferation, migration, and invasion of non-small cell lung cancer: a study based on network pharmacology and in vivo and in vitro experiments].
Li XY; Ma K; Yan JN; You FC; Ma L
Zhongguo Zhong Yao Za Zhi; 2023 Jul; 48(13):3576-3588. PubMed ID: 37474991
[TBL] [Abstract] [Full Text] [Related]
3. Real-World Persistence and Time to Next treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract] [Full Text] [Related]
4. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
[TBL] [Abstract] [Full Text] [Related]
5. Life-threatening infections during treatment for acute lymphoblastic leukemia on the Malaysia-Singapore 2003 and 2010 clinical trials: A risk prediction model.
Oh BLZ; Fan L; Lee SHR; Foo KM; Chiew KH; Seeto ZZL; Chen ZW; Neoh CCC; Liew GSM; Eng JJ; Lam JCM; Quah TC; Tan AM; Chan YH; Yeoh AEJ
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e456-e468. PubMed ID: 35134276
[TBL] [Abstract] [Full Text] [Related]
6. Deviation from delivery of radiation therapy to childhood cancer patients: A retrospective audit.
Agrawal R; Goel V; Anand A; Arora RS
Pediatr Blood Cancer; 2022 Feb; 69(2):e29462. PubMed ID: 34842336
[TBL] [Abstract] [Full Text] [Related]
7. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; de Oliveira JSR; Buccheri V; Perini GF; Dickinson M; McDonald A; Özcan M; Sekiguchi N; Zhu Y; Raut M; Saretsky TL; Nahar A; Kuruvilla J
Blood Adv; 2022 Jan; 6(2):590-599. PubMed ID: 34644372
[TBL] [Abstract] [Full Text] [Related]
8. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract] [Full Text] [Related]
9. Brigatinib in
Heredia D; Barrón F; Cardona AF; Campos S; Rodriguez-Cid J; Martinez-Barrera L; Alatorre J; Salinas MÁ; Lara-Mejia L; Flores-Estrada D; Arrieta O
Future Oncol; 2021 Jan; 17(2):169-181. PubMed ID: 32986959
[No Abstract] [Full Text] [Related]
10. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
11. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M; Pavlakis N; Levchenko E; Platania M; Oliveira J; Novello S; Chiari R; Moran T; Mitry E; Nüesch E; Liu T; Balas B; Konopa K; Peters S
Lung Cancer; 2019 Dec; 138():79-87. PubMed ID: 31654838
[TBL] [Abstract] [Full Text] [Related]
12. Achieving a timely diagnosis for teenagers and young adults with cancer: the ACE "too young to get cancer?" study.
Dommett RM; Pring H; Cargill J; Beynon P; Cameron A; Cox R; Nechowska A; Wint A; Stevens MCG
BMC Cancer; 2019 Jun; 19(1):616. PubMed ID: 31234813
[TBL] [Abstract] [Full Text] [Related]
13. An Age Stratified Analysis of the Access to Care Continuum Across Three Tumor Groups: Are There Delays for AYA?
Pettit T; Sue L; Waugh V; Ballantine K; Gardner K; Bremer L; Pemberton L; Allison L; Adams S; Chou E; Spearing R
J Adolesc Young Adult Oncol; 2019 Aug; 8(4):402-409. PubMed ID: 30912693
[No Abstract] [Full Text] [Related]
14. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
Topp MS; Zimmerman Z; Cannell P; Dombret H; Maertens J; Stein A; Franklin J; Tran Q; Cong Z; Schuh AC
Blood; 2018 Jun; 131(26):2906-2914. PubMed ID: 29739753
[TBL] [Abstract] [Full Text] [Related]
15. Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy.
Smyth E; Zhang S; Cunningham D; Wotherspoon A; Soong R; Peckitt C; Valeri N; Fassan M; Rugge M; Okines A; Allum W; Stenning S; Nankivell M; Langley R; Tan P
Clin Cancer Res; 2017 Dec; 23(24):7543-7549. PubMed ID: 28972045
[No Abstract] [Full Text] [Related]
16. Presentation of childhood cancers to a paediatric shared care unit.
Roskin J; Diviney J; Nanduri V
Arch Dis Child; 2015 Dec; 100(12):1131-5. PubMed ID: 26297700
[TBL] [Abstract] [Full Text] [Related]
17. Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study.
Boldrin E; Rumiato E; Fassan M; Rugge M; Cagol M; Marino D; Chiarion-Sileni V; Ruol A; Gusella M; Pasini F; Amadori A; Saggioro D
Pharmacogenomics J; 2016 Jun; 16(3):266-71. PubMed ID: 26054330
[TBL] [Abstract] [Full Text] [Related]
18. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.
Wheeler HE; Gamazon ER; Stark AL; O'Donnell PH; Gorsic LK; Huang RS; Cox NJ; Dolan ME
Pharmacogenomics J; 2013 Feb; 13(1):35-43. PubMed ID: 21844884
[TBL] [Abstract] [Full Text] [Related]
19. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients.
Strom SS; Estey E; Outschoorn UM; Garcia-Manero G
Leuk Lymphoma; 2010 Apr; 51(4):598-605. PubMed ID: 20141440
[TBL] [Abstract] [Full Text] [Related]
20. [Multivariate analysis of risk of cardiac complications in Hodgkin's lymphoma].
Podol'skiĭ PN; Datsenko PV; Pan'shin GA; Sotnikov VM; Mel'nik IuD; Ivashin AV; Bozhenko VK
Vopr Onkol; 2009; 55(4):447-50. PubMed ID: 19947368
[TBL] [Abstract] [Full Text] [Related]
[Next]
